Belite Bio Inc ADR (BLTE) - Net Assets
Based on the latest financial reports, Belite Bio Inc ADR (BLTE) has net assets worth $274.08 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($282.39 Million) and total liabilities ($8.31 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Belite Bio Inc ADR (BLTE) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $274.08 Million |
| % of Total Assets | 97.06% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 28.32 |
Belite Bio Inc ADR - Net Assets Trend (2020–2024)
This chart illustrates how Belite Bio Inc ADR's net assets have evolved over time, based on quarterly financial data. Also explore BLTE total assets for the complete picture of this company's asset base.
Annual Net Assets for Belite Bio Inc ADR (2020–2024)
The table below shows the annual net assets of Belite Bio Inc ADR from 2020 to 2024. For live valuation and market cap data, see how much is Belite Bio Inc ADR worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $145.82 Million | +61.25% |
| 2023-12-31 | $90.43 Million | +117.90% |
| 2022-12-31 | $41.50 Million | +374.97% |
| 2021-12-31 | $-15.09 Million | -114.48% |
| 2020-12-31 | $-7.04 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Belite Bio Inc ADR's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9009000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | 0.00% |
| Other Comprehensive Income | $-660.00K | -0.45% |
| Other Components | $254.12 Million | 174.27% |
| Total Equity | $145.82 Million | 100.00% |
Belite Bio Inc ADR Competitors by Market Cap
The table below lists competitors of Belite Bio Inc ADR ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tube Investments of India Limited
NSE:TIINDIA
|
$6.17 Billion |
|
COM.INTL BK GDR S LE 10
F:CIN
|
$6.17 Billion |
|
Mohawk Industries Inc
NYSE:MHK
|
$6.18 Billion |
|
Accelleron Industries AG
SW:ACLN
|
$6.18 Billion |
|
Colgate Palmolive (India) Limited
NSE:COLPAL
|
$6.17 Billion |
|
Sealed Air Corporation
NYSE:SEE
|
$6.16 Billion |
|
Brinker International Inc
NYSE:EAT
|
$6.16 Billion |
|
AB Sagax (publ)
ST:SAGA-B
|
$6.16 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Belite Bio Inc ADR's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 90,431,000 to 145,821,000, a change of 55,390,000 (61.3%).
- Net loss of 36,144,000 reduced equity.
- New share issuances of 42,236,000 increased equity.
- Other comprehensive income decreased equity by 286,000.
- Other factors increased equity by 49,584,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-36.14 Million | -24.79% |
| Share Issuances | $42.24 Million | +28.96% |
| Other Comprehensive Income | $-286.00K | -0.2% |
| Other Changes | $49.58 Million | +34.0% |
| Total Change | $- | 61.25% |
Book Value vs Market Value Analysis
This analysis compares Belite Bio Inc ADR's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 34.44x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-0.76 | $164.45 | x |
| 2021-12-31 | $-0.63 | $164.45 | x |
| 2022-12-31 | $2.08 | $164.45 | x |
| 2023-12-31 | $3.40 | $164.45 | x |
| 2024-12-31 | $4.78 | $164.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Belite Bio Inc ADR utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.79%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.04x
- Recent ROE (-24.79%) is below the historical average (-18.05%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.05 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.16 Million |
| 2022 | -30.48% | 0.00% | 0.00x | 1.07x | $-16.80 Million |
| 2023 | -34.98% | 0.00% | 0.00x | 1.05x | $-40.68 Million |
| 2024 | -24.79% | 0.00% | 0.00x | 1.04x | $-50.73 Million |
Industry Comparison
This section compares Belite Bio Inc ADR's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Belite Bio Inc ADR (BLTE) | $274.08 Million | 0.00% | 0.03x | $6.17 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Belite Bio Inc ADR
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and … Read more